My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC - Episode 15

Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)

September 3, 2024

Dr. Laurence Albiges, MD, PhD, reviews the recent findings presented at the American Society of Clinical Oncology (ASCO) 2024 meeting, specifically focusing on the results of the phase 3 STELLAR trial.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Evolving Treatment Standards in Non-Clear Cell RCC

EP. 2: Extended Follow Up of KEYNOTE-B61

EP. 3: Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

EP. 4: STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

EP. 5: Case Presentation: 61-year-old male Renal Cell Carcinoma

EP. 6: Use of Combination Regimens in Frontline RCC

EP. 7: Treatment Decision Making in first-line combinations for advanced RCC

EP. 8: AE Management for Combination Regimens in Advanced RCC

EP. 9: AE Management for Combination Regimens in Advanced RCC

EP. 10: Optimizing Treatment in Advanced RCC

EP. 11: Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile

EP. 12: Updates in the Treatment Approach for Non-clear cell RCC

EP. 13: Dr Albiges Reviews Long term follow up data from KEYNOTE-B61

EP. 14: Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC

Now Viewing

EP. 15: Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)

EP. 16: Summary and Forward Looking for RCC

Video content above is prompted by the following:

Please discuss the recent data presented at ASCO 2024 on the phase 3 STELLAR trial
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study (Abstract TPS4611)